Ezetimibe ameliorates early diabetic nephropathy in db/db mice

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic nephropathy is a significant complication of diabetes, often associated with lipid abnormalities.
• Lipid-lowering medications are being investigated for their potential benefits in chronic kidney disease (CKD).
• The specific effect of ezetimibe on diabetic nephropathy is not well-established.

Purpose of the Study:

• To investigate the protective effects of ezetimibe on diabetic nephropathy in a mouse model.
• To determine if ezetimibe influences key markers of kidney damage and metabolic parameters in diabetic mice.

Main Methods:

• Db/db mice were administered ezetimibe (0.01% w/w) in their diet for 8 weeks.
• Key metabolic, lipid, and renal parameters were assessed, including plasma lipids, glucose, albuminuria, and kidney histology.
• Markers of oxidative stress and adiponectin signaling were also evaluated.

Main Results:

• Ezetimibe significantly reduced plasma and hepatic lipid levels and decreased urinary albumin excretion by 50%.
• The drug improved glomerular hypertrophy but did not affect body weight, food intake, adiposity, blood pressure, or glucose metabolism.
• Ezetimibe normalized plasma adiponectin levels and increased kidney adiponectin receptor 1 expression, without impacting oxidative stress.

Conclusions:

• Ezetimibe demonstrates renoprotective effects in early diabetic nephropathy, primarily through its hypolipidemic action.
• Amelioration of adiponectin resistance may represent an additional mechanism underlying ezetimibe's beneficial effects on the kidney.